Trial Profile
A comparative, pilot study of ranibizumab and aflibercept in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 14 Oct 2016 New trial record